All Categories
 
Categories
Contributors
Tags
Melanoma X
PPI(1)
 
   
2 items found in 1 pages
The REFINE trial: how can we improve the way we give cancer immunotherapy?
Immunotherapy drugs fight cancer by helping the immune system recognise and attack cancer cells. These drugs have revolutionised cancer treatment over the last decade, improving survival for many people with different types of cancer. However, researchers are still unsure of the best way to give immunotherapy, which can come with unpredictable side effects. In this episode, Clinical Fellow Sophie Merrick discusses how the REFINE trial hopes to address this problem, by testing if giving immunotherapy less frequently can still treat the cancer effectively, whilst improving the quality of life for patients, reducing side effects and costs. Further information is available on the REFINE study page at www.mrcctu.ac.uk For questions or feedback on the series, message us at mrcctu.engage@ucl.ac.uk For more information and to access the transcript: https://bit.ly/3DgIDE2
0
7/18/2023
Cancer Institute Seminar Series - Luca Gerosa
Dr Luca Gerosa, Harvard Medical School, presents: 'Adaptive ERK pulses enable persistence of BRAF-mutant melanoma cells during targeted therapy.' 18 May 2020 Hosted by Prof Bart Vanhaesebroeck
180
5/22/2020